Skip to main content
SpringerLink
Log in
Book cover

Coloproctology pp 261–285Cite as

Personalised Genomics and Molecular Profiles in Colorectal Cancer: Towards Precision Cancer Care

  • Chapter
  • First Online:

  • 592 Accesses

Abstract

Colorectal cancer represents a heterogeneous disease with variations in disease course and clinical outcomes. Currently staging tools (e.g. the TNM system) do not reflect this heterogeneity and could lead to under- and overtreatment. There is a need for more precise and personalized stratification tools that may both predict disease course as well as response to therapy. The need for better knowledge of genetic risk factors and associated cancer biology may evolve through evolving ‘omics’ technology. More work is needed to translate basic science into clinical advances. This chapter reviews developments and challenges towards personalized, precision cancer care in colorectal cancer patients.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–502.

    Article  PubMed  Google Scholar 

  2. Nedrebø BS, Søreide K, Eriksen MT, Dørum LM, Kvaløy JT, Søreide JA, et al. Survival effect of implementing national treatment strategies for curatively resected colonic and rectal cancer. Br J Surg. 2011;98(5):716–23.

    Article  PubMed  Google Scholar 

  3. Fakih MG. Metastatic colorectal cancer: current state and future directions. J Clin Oncol. 2015;33(16):1809–24.

    Article  CAS  PubMed  Google Scholar 

  4. Søreide K, Berg M, Skudal BS, Nedrebø BS. Advances in the understanding and treatment of colorectal cancer. Discov Med. 2011;12(66):393–404.

    Google Scholar 

  5. Stoffel EM, Boland CR. Genetics and genetic testing in hereditary colorectal cancer. Gastroenterology. 2015;149(5):1191–203.e2.

    Google Scholar 

  6. Puppa G, Sonzogni A, Colombari R, Pelosi G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch Pathol Lab Med. 2010;134(6):837–52.

    PubMed  Google Scholar 

  7. Nagtegaal ID, Quirke P, Schmoll HJ. Has the new TNM classification for colorectal cancer improved care? Nat Rev Clin Oncol. 2012;9(2):119–23.

    Article  Google Scholar 

  8. Marshall JL. Risk assessment in Stage II colorectal cancer. Oncology (Williston Park). 2010;24(1 Suppl 1):9–13.

    Google Scholar 

  9. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.

    Article  PubMed  CAS  Google Scholar 

  10. Hong TS, Ryan DP. Adjuvant chemotherapy for locally advanced rectal cancer: is it a given? J Clin Oncol. 2015;33(17):1878–80.

    Article  PubMed  Google Scholar 

  11. Hagland HR, Berg M, Jolma IW, Carlsen A, Soreide K. Molecular pathways and cellular metabolism in colorectal cancer. Dig Surg. 2013;30(1):12–25.

    Article  CAS  PubMed  Google Scholar 

  12. Berg M, Søreide K. EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med. 2012;14(76):207–14.

    PubMed  Google Scholar 

  13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  PubMed  Google Scholar 

  14. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860–921.

    Article  CAS  PubMed  Google Scholar 

  15. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304–51.

    Article  CAS  PubMed  Google Scholar 

  16. Beggs AD, Dilworth MP. Surgery in the era of the 'omics revolution. Br J Surg. 2015;102(2):e29–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Lugli A. Towards a molecular classification of colorectal cancer. Front Oncol. 2015;5:46.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Linnekamp JF, Wang X, Medema JP, Vermeulen L. Colorectal cancer heterogeneity and targeted therapy: a case for molecular disease subtypes. Cancer Res. 2015;75(2):245–9.

    Article  CAS  PubMed  Google Scholar 

  19. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Leong KJ, Beggs A, James J, Morton DG, Matthews GM, Bach SP. Biomarker-based treatment selection in early-stage rectal cancer to promote organ preservation. Br J Surg. 2014;101(10):1299–309.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Søreide K. Endoscopic surveillance after curative surgery for sporadic colorectal cancer: patient-tailored, tumor-targeted or biology-driven? Scand J Gastroenterol. 2010;45(10):1255–61.

    Article  PubMed  Google Scholar 

  22. Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA, Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102(10):1175–83.

    Article  CAS  PubMed  Google Scholar 

  23. Søreide K, Sandvik OM, Søreide JA. KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: a biomarker of cancer biology or a byproduct of patient selection? Cancer. 2014;120(24):3862–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  24. Lea D, Haland S, Hagland HR, Søreide K. Accuracy of TNM staging in colorectal cancer: a review of current culprits, the modern role of morphology and stepping-stones for improvements in the molecular era. Scand J Gastroenterol. 2014;49(10):1153–63.

    Article  PubMed  Google Scholar 

  25. Quirke P, Williams GT, Ectors N, Ensari A, Piard F, Nagtegaal I. The future of the TNM staging system in colorectal cancer: time for a debate? Lancet Oncol. 2007;8(7):651–7.

    Article  PubMed  Google Scholar 

  26. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol. 2014;232(2):199–209.

    Article  CAS  PubMed  Google Scholar 

  27. Cascinu S, Staccioli MP, Gasparini G, Giordani P, Catalano V, Ghiselli R, et al. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res. 2000;6(7):2803–7.

    CAS  PubMed  Google Scholar 

  28. Veen T, Stormark K, Nedrebø BS, Berg M, Søreide JA, Kørner H, et al. Long-term follow-up and survivorship after completing systematic surveillance in stage I–III colorectal cancer: who is still at risk? J Gastrointest Cancer. 2015;46(3):259–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Veen T, Nedrebø BS, Stormark K, Søreide JA, Kørner H, Søreide K. Qualitative and quantitative issues of lymph nodes as prognostic factor in colon cancer. Dig Surg. 2013;30(1):1–11.

    Article  CAS  PubMed  Google Scholar 

  30. Nordgard O, Oltedal S, Aasprong OG, Søreide JA, Søreide K, Tjensvoll K, et al. Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients. Ann Surg Oncol. 2012;19(12):3719–26.

    Article  PubMed  Google Scholar 

  31. Nedrebø BS, Søreide K, Nesbakken A, Eriksen MT, Søreide JA, Kørner H. Risk factors associated with poor lymph node harvest after colon cancer surgery in a national cohort. Colorectal Dis. 2013;15(6):e301–8.

    Article  PubMed  Google Scholar 

  32. Berg M, Guriby M, Nordgard O, Nedrebø BS, Ahlquist TC, Smaaland R, et al. Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I–III colon cancers. Mol Med. 2013;19:286–93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Søreide K, Nedrebø BS, Søreide JA, Slewa A, Kørner H. Lymph node harvest in colon cancer: influence of microsatellite instability and proximal tumor location. World J Surg. 2009;33(12):2695–703.

    Article  PubMed  Google Scholar 

  34. Nagtegaal ID, Quirke P. Colorectal tumour deposits in the mesorectum and pericolon; a critical review. Histopathology. 2007;51(2):141–9.

    Article  CAS  PubMed  Google Scholar 

  35. SobinLH, WittekindCh, editors. International Union Against Cancer (UICC). TNM classification of malignant tumors. 5th ed. New York: John Wiley & Sons, Inc., 1997.

    Google Scholar 

  36. Goldstein NS, Turner JR. Pericolonic tumor deposits in patients with T3N+MO colon adenocarcinomas: markers of reduced disease free survival and intra-abdominal metastases and their implications for TNM classification. Cancer. 2000;88(10):2228–38.

    Article  CAS  PubMed  Google Scholar 

  37. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 6th ed. Hoboken, New Jersey: John Wiley & Sons; 2002.

    Google Scholar 

  38. Wunsch K, Muller J, Jahnig H, Herrmann RA, Arnholdt HM, Markl B. Shape is not associated with the origin of pericolonic tumor deposits. Am J Clin Pathol. 2010;133(3):388–94.

    Article  PubMed  Google Scholar 

  39. Nagtegaal ID, Tot T, Jayne DG, McShane P, Nihlberg A, Marshall HC, et al. Lymph nodes, tumor deposits, and TNM: are we getting better? J Clin Oncol. 2011;29(18):2487–92.

    Article  PubMed  Google Scholar 

  40. Sobin LH, Gospodarowicz MK, Wittekind C. UICC International Union against Cancer. TNM Classification of Tumors. 7th ed. UK: Oxford 2010.

    Google Scholar 

  41. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. New York: Springer; 2010. 649p

    Google Scholar 

  42. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264–71.

    Article  PubMed  Google Scholar 

  43. AJCC. Cancer staging manual. 7th ed. Chicago, IL: Springer; 2010. 649p

    Google Scholar 

  44. Lan YT, Yang SH, Chang SC, Liang WY, Li AF, Wang HS, et al. Analysis of the seventh edition of American Joint Committee on colon cancer staging. Int J Colorectal Dis. 2012;27(5):657–63.

    Article  PubMed  Google Scholar 

  45. Compton CC. Key issues in reporting common cancer specimens: problems in pathologic staging of colon cancer. Arch Pathol Lab Med. 2006;130(3):318–24.

    PubMed  Google Scholar 

  46. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319(9):525–32.

    Article  CAS  PubMed  Google Scholar 

  47. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.

    Article  CAS  PubMed  Google Scholar 

  48. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113–30.

    Article  CAS  PubMed  Google Scholar 

  49. Kang GH. Four molecular subtypes of colorectal cancer and their precursor lesions. Arch Pathol Lab Med. 2011;135(6):698–703.

    PubMed  Google Scholar 

  50. Watson MM, Berg M, Søreide K. Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer. Br J Cancer. 2014;111(5):823–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology. 2015;149(5):1204–25.e12.

    Google Scholar 

  53. Berg M, Søreide K. Genetic and epigenetic traits as biomarkers in colorectal cancer. Int J Mol Sci. 2011;12(12):9426–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Yamamoto E, Suzuki H, Yamano HO, Maruyama R, Nojima M, Kamimae S, et al. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Am J Pathol. 2012;181(5):1847–61.

    Article  CAS  PubMed  Google Scholar 

  55. Berg M, Hagland HR, Søreide K. Comparison of CpG island methylator phenotype (CIMP) frequency in colon cancer using different probe- and gene-specific scoring alternatives on recommended multi-gene panels. PLoS One. 2014;9(1):e86657.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology. 2015;148(1):77–87.e2.

    Google Scholar 

  57. Lee SY, Miyai K, Han HS, Hwang DY, Seong MK, Chung H, et al. Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia. Dig Dis Sci. 2012;57(1):72–8.

    Article  CAS  PubMed  Google Scholar 

  58. Lee SY, Chung H, Devaraj B, Iwaizumi M, Han HS, Hwang DY, et al. Microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasias. Gastroenterology. 2010;139(5):1519–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Venderbosch S, van Lent-van Vliet S, de Haan AF, Ligtenberg MJ, Goossens M, Punt CJ, et al. EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer. PLoS One. 2015;10(4):e0124538.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Carethers JM, Jung BH. Genetics and genetic biomarkers in sporadic colorectal cancer. Gastroenterology. 2015;149(5):1177–90.e3.

    Google Scholar 

  61. Søreide K, Nedrebø BS, Knapp JC, Glomsaker TB, Søreide JA, Kørner H. Evolving molecular classification by genomic and proteomic biomarkers in colorectal cancer: potential implications for the surgical oncologist. Surg Oncol. 2009;18(1):31–50.

    Article  PubMed  Google Scholar 

  62. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268–74.

    Article  PubMed  CAS  Google Scholar 

  63. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853):1108–13.

    Article  CAS  PubMed  Google Scholar 

  64. CGAN. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.

    Google Scholar 

  65. Vilar E, Tabernero J, Gruber SB. Micromanaging the classification of colon cancer: the role of the microRNAome. Clin Cancer Res. 2011;17(23):7207–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Tuna M, Machado AS, Calin GA. Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. Genes Chromosomes Cancer. 2016;55(3):193–214.

    Article  CAS  PubMed  Google Scholar 

  67. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–4.

    Article  CAS  PubMed  Google Scholar 

  68. Bos PD, Rudensky AY. Treg cells in cancer: a case of multiple personality disorder. Sci Transl Med. 2012;4(164):164fs44.

    Article  PubMed  CAS  Google Scholar 

  69. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397–411.

    Article  PubMed  Google Scholar 

  71. Ogino S, Campbell PT, Nishihara R, Phipps AI, Beck AH, Sherman ME, et al. Proceedings of the second international molecular pathological epidemiology (MPE) meeting. Cancer Causes Control. 2015;26(7):959–72.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012;12(6):621–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. De Sousa EMF, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LP, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614–8.

    Article  CAS  Google Scholar 

  74. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 2013;10(5):e1001453.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Konda K, Konishi K, Yamochi T, Ito YM, Nozawa H, Tojo M, et al. Distinct molecular features of different macroscopic subtypes of colorectal neoplasms. PLoS One. 2014;9(8):e103822.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Agesen TH, Sveen A, Merok MA, Lind GE, Nesbakken A, Skotheim RI, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut. 2012;61(11):1560–7.

    Article  PubMed  CAS  Google Scholar 

  78. Sveen A, Agesen TH, Nesbakken A, Meling GI, TO R, Liestol K, et al. ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients. Clin Cancer Res. 2012;18(21):6001–10.

    Article  CAS  PubMed  Google Scholar 

  79. Calon A, Lonardo E, Berenguer-Llergo A, Espinet E, Hernando-Momblona X, Iglesias M, et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet. 2015;47(4):320–9.

    Article  CAS  PubMed  Google Scholar 

  80. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo JA, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer. 2012;12:260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231(1):63–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Park YY, Lee SS, Lim JY, Kim SC, Kim SB, Sohn BH, et al. Comparison of prognostic genomic predictors in colorectal cancer. PLoS One. 2013;8(4):e60778.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Song Q, Merajver SD, Li JZ. Cancer classification in the genomic era: five contemporary problems. Hum Genomics. 2015;9:27.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  84. Gagan J, Van Allen EM. Next-generation sequencing to guide cancer therapy. Genome Med. 2015;7(1):80.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Simbolo M, Mafficini A, Agostini M, Pedrazzani C, Bedin C, Urso ED, et al. Next-generation sequencing for genetic testing of familial colorectal cancer syndromes. Hered Cancer Clin Pract. 2015;13(1):18.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Carrick DM, Mehaffey MG, Sachs MC, Altekruse S, Camalier C, Chuaqui R, et al. Robustness of next generation sequencing on older formalin-fixed paraffin-embedded tissue. PLoS One. 2015;10(7):e0127353.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol. 2014;15(6):601–11.

    Article  CAS  PubMed  Google Scholar 

  88. Primrose JN, Cunningham D, Garden OJ, Maughan TS, Pugh SA, Stanton L, et al. Cetuximab is contraindicated in the perioperative treatment of colorectal liver metastases. J Clin Oncol. 2015;33(21):2405–6.

    Article  CAS  PubMed  Google Scholar 

  89. Nordlinger BM, Poston GJ, Goldberg RM. Reply to J.N. Primrose et al and C.-H. Kohne. J Clin Oncol. 2015;33(21):2408–9.

    Article  PubMed  Google Scholar 

  90. Malapelle U, Carlomagno C, de Luca C, Bellevicine C, Troncone G. KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond. J Clin Pathol. 2014;67(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  91. Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol. 2016;34(2):179–85.

    Article  CAS  PubMed  Google Scholar 

  92. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753–62.

    Article  PubMed  CAS  Google Scholar 

  93. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, et al. Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer. J Clin Oncol. 2015;33(34):4032–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–81.

    Article  CAS  PubMed  Google Scholar 

  95. Di Caro G, Bergomas F, Grizzi F, Doni A, Bianchi P, Malesci A, et al. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res. 2014;20(8):2147–58.

    Article  PubMed  CAS  Google Scholar 

  96. Roxburgh CS, McMillan DC. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat Rev. 2012;38(5):451–66.

    Article  CAS  PubMed  Google Scholar 

  97. Curtis NJ, Primrose JN, Thomas GJ, Mirnezami AH, Ottensmeier CH. The adaptive immune response to colorectal cancer: from the laboratory to clinical practice. Eur J Surg Oncol. 2012;38(10):889–96.

    Article  CAS  PubMed  Google Scholar 

  98. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6):610–8.

    Article  PubMed  Google Scholar 

  99. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44.

    Article  CAS  PubMed  Google Scholar 

  100. Chaput N, Svrcek M, Auperin A, Locher C, Drusch F, Malka D, et al. Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer. Br J Cancer. 2013;109(4):1013–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4(4):330–6.

    Article  CAS  PubMed  Google Scholar 

  102. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res. 2003;9(2):606–12.

    PubMed  Google Scholar 

  103. Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D. In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer. J Transl Med. 2006;4:52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Kim M, Grimmig T, Grimm M, Lazariotou M, Meier E, Rosenwald A, et al. Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One. 2013;8(1):e53630.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med. 2012;10(1):205.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944–51.

    Article  CAS  PubMed  Google Scholar 

  107. Young GP, Symonds EL, Allison JE, Cole SR, Fraser CG, Halloran SP, et al. Advances in fecal occult blood tests: the FIT revolution. Dig Dis Sci. 2015;60(3):609–22.

    Article  PubMed  Google Scholar 

  108. Müller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, Zitt M, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363(9417):1283–5.

    Article  PubMed  CAS  Google Scholar 

  109. Huang Z, Li L, Wang J. Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci. 2007;52(9):2287–91.

    Article  PubMed  Google Scholar 

  110. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61(5):739–45.

    Article  CAS  PubMed  Google Scholar 

  111. Altomare DF, Di Lena M, Porcelli F, Trizio L, Travaglio E, Tutino M, et al. Exhaled volatile organic compounds identify patients with colorectal cancer. Br J Surg. 2013;100(1):144–50.

    Article  CAS  PubMed  Google Scholar 

  112. Jamshidi F, TO N, Huntsman DG. Cancer genomics: why rare is valuable. J Mol Med (Berl). 2015;93(4):369–81.

    Article  CAS  Google Scholar 

  113. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Ellermeier C, Vang S, Cleveland K, Durand W, Resnick MB, Brodsky AS. Prognostic microRNA expression signature from examination of colorectal primary and metastatic tumors. Anticancer Res. 2014;34(8):3957–67.

    CAS  PubMed  Google Scholar 

  115. Gemoll T, Meyer R, Habermann JK. Applying genomics and proteomics in translational surgical oncology research. Eur Surg Res. 2015;55(3):184–97.

    Article  CAS  PubMed  Google Scholar 

  116. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31(15):1834–41.

    Article  PubMed  Google Scholar 

  118. Dienstmann R, Salazar R, Tabernero J. The evolution of our molecular understanding of colorectal cancer: what we are doing now, what the future holds, and how tumor profiling is just the beginning. Am Soc Clin Oncol Educ Book. 2014:91–9.

    Google Scholar 

  119. Maughan TS, Meade AM, Adams RA, Richman SD, Butler R, Fisher D, et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? Br J Cancer. 2014;110(9):2178–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Richman SD, Adams R, Quirke P, Butler R, Hemmings G, Chambers P, et al. Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. J Clin Pathol. 2016;69(1):35–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Kjetil Søreide MD, PhD

  2. Department of Gastrointestinal Surgery and Gastrointestinal Translational Research Unit, Laboratory of Molecular Biology, Stavanger University Hospital, P.O. Box 8100, 4068, Stavanger, Norway

    Kjetil Søreide MD, PhD

  3. Department of Pathology and Gastrointestinal Translational Research Unit, Stavanger University Hospital, Stavanger, Norway

    Dordi Lea MD

Authors
  1. Kjetil Søreide MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dordi Lea MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kjetil Søreide MD, PhD .

Editor information

Editors and Affiliations

  1. Colorectal Surgery, Singleton Hospital, Swansea, United Kingdom

    John Beynon

  2. Department of Colorectal Surgery, Singleton Hospital, Swansea, United Kingdom

    Dean Anthony Harris

  3. Department of Colorectal Surgery, Singleton Hospital, Swansea, United Kingdom

    Mark Davies

  4. Department of Colorectal Surgery, Singleton Hospital, Swansea, United Kingdom

    Martyn Evans

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Søreide, K., Lea, D. (2017). Personalised Genomics and Molecular Profiles in Colorectal Cancer: Towards Precision Cancer Care. In: Beynon, J., Harris, D., Davies, M., Evans, M. (eds) Coloproctology. Springer, Cham. https://doi.org/10.1007/978-3-319-55957-5_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-55957-5_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-55955-1

  • Online ISBN: 978-3-319-55957-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation